PLRX
Pliant Therapeutics, Inc.
Biotechnology
Market Cap$70M
5Y Perf.-96.5%
Build Your Comparison
Side-by-side financial analysisPLRX
IDYA
Try popular comparisons:
Stock Comparison
PLRX vs IDYA
Revenue, margins, valuation, and 5-year total return — side by side.
IDYA
IDEAYA Biosciences, Inc.
Biotechnology
Market Cap$2.55B
5Y Perf.+103.9%
PLRX vs IDYA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  PLRX |  IDYA |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $70M | $2.55B |
| Revenue (TTM) | $0.00 | $225M |
| Net Income (TTM) | $-113M | $-140M |
| Gross Margin | — | 99.5% |
| Operating Margin | — | -81.4% |
| Total Debt | $29M | $28M |
| Cash & Equiv. | $45M | $113M |
PLRX vs IDYA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
PLRX
IDYA
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| Pliant Therapeutics… (PLRX) | 100 | 3.5 | -96.5% |
| IDEAYA Biosciences,… (IDYA) | 100 | 203.9 | +103.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PLRX vs IDYA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: IDYA leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. Pliant Therapeutics, Inc. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
🥇IDYA emerged as the overall leader. Track its performance:
PLRX
Pliant Therapeutics, Inc.
The Income Pick
PLRX is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 1.14
- Lower volatility, beta 1.14, Low D/E 16.1%, current ratio 12.00x
- Beta 1.14, current ratio 12.00x
Best for: income & stability and sleep-well-at-night
IDYA
IDEAYA Biosciences, Inc.
The Growth Play
IDYA carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 30.2%, EPS growth 61.9%, 3Y rev CAGR 62.5%
- 159.0% 10Y total return vs PLRX's -94.7%
- 30.2% revenue growth vs PLRX's 48.6%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  IDYA | 30.2% revenue growth vs PLRX's 48.6% |
| Quality / Margins |  PLRX | -1.1% margin vs IDYA's -62.2% |
| Stability / Safety | PLRX | Beta 1.14 vs IDYA's 1.25 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | IDYA | +30.1% vs PLRX's -23.1% |
| Efficiency (ROA) | IDYA | -12.8% ROA vs PLRX's -45.1%, ROIC -12.4% vs -49.2% |
PLRX vs IDYA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
PLRX vs IDYA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLIDYALAGGINGPLRX
PLRXPliant Therapeutics, …
1leads
IDYAIDEAYA Biosciences, I…
2leads
6 Total Categories
CATEGORYLEADERvs PLRXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
PLRX1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
IDYA8/8
Total Returns1Y, 3Y, 5Y total returns with dividends
IDYA5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
PLRX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
IDYA and PLRX operate at a comparable scale, with $225M and $0 in trailing revenue.
| Metric | PLRXPliant Therapeuti… | IDYAIDEAYA Bioscience… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $225M |
| EBITDAEarnings before interest/tax | -$118M | -$179M |
| Net IncomeAfter-tax profit | -$113M | -$140M |
| Free Cash FlowCash after capex | -$99M | -$88M |
| Gross MarginGross profit ÷ Revenue | — | +99.5% |
| Operating MarginEBIT ÷ Revenue | — | -81.4% |
| Net MarginNet income ÷ Revenue | — | -62.2% |
| FCF MarginFCF ÷ Revenue | — | -39.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +65.2% | -35.4% |
PLRX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — PLRX and IDYA each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | PLRXPliant Therapeuti… | IDYAIDEAYA Bioscience… |
|---|---|---|
| Market CapShares × price | $70M | $2.5B |
| Enterprise ValueMkt cap + debt − cash | $54M | $2.5B |
| Trailing P/EPrice ÷ TTM EPS | -0.47x | -22.64x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 11.64x |
| Price / BookPrice ÷ Book value/share | 0.38x | 2.51x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — PLRX and IDYA each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
IDYA leads this category, winning 8 of 8 comparable metrics.
Profitability & Efficiency
IDYA delivers a -14.0% return on equity — every $100 of shareholder capital generates $-14 in annual profit, vs $-59 for PLRX. IDYA carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to PLRX's 0.16x. On the Piotroski fundamental quality scale (0–9), IDYA scores 4/9 vs PLRX's 3/9, reflecting mixed financial health.
| Metric | PLRXPliant Therapeuti… | IDYAIDEAYA Bioscience… |
|---|---|---|
| ROE (TTM)Return on equity | -59.1% | -14.0% |
| ROA (TTM)Return on assets | -45.1% | -12.8% |
| ROICReturn on invested capital | -49.2% | -12.4% |
| ROCEReturn on capital employed | -52.4% | -15.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.16x | 0.03x |
| Net DebtTotal debt minus cash | -$16M | -$85M |
| Cash & Equiv.Liquid assets | $45M | $113M |
| Total DebtShort + long-term debt | $29M | $28M |
| Interest CoverageEBIT ÷ Interest expense | -29.83x | — |
IDYA leads this category, winning 8 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
IDYA leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IDYA five years ago would be worth $13,185 today (with dividends reinvested), compared to $343 for PLRX. Over the past 12 months, IDYA leads with a +30.1% total return vs PLRX's -23.1%. The 3-year compound annual growth rate (CAGR) favors IDYA at 4.8% vs PLRX's -63.2% — a key indicator of consistent wealth creation.
| Metric | PLRXPliant Therapeuti… | IDYAIDEAYA Bioscience… |
|---|---|---|
| YTD ReturnYear-to-date | -9.6% | -14.4% |
| 1-Year ReturnPast 12 months | -23.1% | +30.1% |
| 3-Year ReturnCumulative with dividends | -95.0% | +15.0% |
| 5-Year ReturnCumulative with dividends | -96.6% | +31.8% |
| 10-Year ReturnCumulative with dividends | -94.7% | +159.0% |
| CAGR (3Y)Annualised 3-year return | -63.2% | +4.8% |
IDYA leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — PLRX and IDYA each lead in 1 of 2 comparable metrics.
Risk & Volatility
PLRX is the less volatile stock with a 1.14 beta — it tends to amplify market swings less than IDYA's 1.25 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IDYA currently trades 73.8% from its 52-week high vs PLRX's 57.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PLRXPliant Therapeuti… | IDYAIDEAYA Bioscience… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.14x | 1.25x |
| 52-Week HighHighest price in past year | $1.95 | $39.28 |
| 52-Week LowLowest price in past year | $1.09 | $20.50 |
| % of 52W HighCurrent price vs 52-week peak | +57.9% | +73.8% |
| RSI (14)Momentum oscillator 0–100 | 40.5 | 48.8 |
| Avg Volume (50D)Average daily shares traded | 481K | 1.3M |
Evenly matched — PLRX and IDYA each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | PLRXPliant Therapeuti… | IDYAIDEAYA Bioscience… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $58.67 |
| # AnalystsCovering analysts | — | 25 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
IDYA leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). PLRX leads in 1 (Income & Cash Flow). 2 tied.
Best OverallIDEAYA Biosciences, Inc. (IDYA)Leads 2 of 6 categories
Loading custom metrics...
PLRX vs IDYA: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is PLRX or IDYA a better buy right now?
Analysts rate IDEAYA Biosciences, Inc.
(IDYA) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PLRX or IDYA?
Over the past 5 years, IDEAYA Biosciences, Inc.
(IDYA) delivered a total return of +31. 8%, compared to -96. 6% for Pliant Therapeutics, Inc. (PLRX). Over 10 years, the gap is even starker: IDYA returned +159. 0% versus PLRX's -94. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PLRX or IDYA?
By beta (market sensitivity over 5 years), Pliant Therapeutics, Inc.
(PLRX) is the lower-risk stock at 1. 14β versus IDEAYA Biosciences, Inc. 's 1. 25β — meaning IDYA is approximately 10% more volatile than PLRX relative to the S&P 500. On balance sheet safety, IDEAYA Biosciences, Inc. (IDYA) carries a lower debt/equity ratio of 3% versus 16% for Pliant Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — PLRX or IDYA?
On earnings-per-share growth, the picture is similar: IDEAYA Biosciences, Inc.
grew EPS 61. 9% year-over-year, compared to 30. 0% for Pliant Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — PLRX or IDYA?
Pliant Therapeutics, Inc.
(PLRX) is the more profitable company, earning 0. 0% net margin versus -52. 0% for IDEAYA Biosciences, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PLRX leads at 0. 0% versus -72. 8% for IDYA. At the gross margin level — before operating expenses — IDYA leads at 97. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — PLRX or IDYA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is PLRX or IDYA better for a retirement portfolio?
For long-horizon retirement investors, IDEAYA Biosciences, Inc.
(IDYA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 25), +159. 0% 10Y return). Both have compounded well over 10 years (IDYA: +159. 0%, PLRX: -94. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between PLRX and IDYA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: PLRX is a small-cap quality compounder stock; IDYA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.